Drugs / MK-4716
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07247110 | Dec 2025 → Dec 2030 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4716 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07247110 ↗ |
| Route | Oral | “Oral administration” NCT07247110 ↗ |